Paragon Associates & Paragon Associates Ii Joint Venture Lumos Pharma, Inc. Transaction History

Paragon Associates & Paragon Associates Ii Joint Venture

$54 Million
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 15, 2021	SELL	$7.36 - $11.36 $368,000 - $568,000	-50,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.75 - $13.44 $487,500 - $672,000	50,000 New	50,000 $500,000

Others Institutions Holding LUMO

# of Institutions

Shares Held

2.2M

Call Options Held

Put Options Held

Private Advisor Group, LLC

745K
Shares

$3.22 Million
0.02% of portfolio
Goldman Sachs Group Inc New York, NY

362K
Shares

$1.57 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

244K
Shares

$1.06 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

214K
Shares

$925,814
0.0% of portfolio
Jefferies Financial Group Inc. New York, NY

121K
Shares

$522,418
0.0% of portfolio

View Full List

About LUMOS PHARMA, INC.

Ticker LUMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,396,070
Market Cap $36.4M
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...

More about LUMO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Paragon Associates & Paragon Associates Ii Joint Venture, based on Form 13F filings with the SEC.

News

Stay updated on Paragon Associates & Paragon Associates Ii Joint Venture with notifications on news.

Account